- Single R&D organisation in place, including new leadership team, global organisation structure and governance framework
- Vimovo approved in the US and the EU; Brilique approved in the EU with Complete Response Letter received for Brilinta in the US; Kombiglyze XRTM (OnglyzaTM/metformin combination) approved in the US; decisions made in December to discontinue development of motavizumab and Certriad
- Completed a deal with Rigel for the Phase III development of fostamatinib (for rheumatoid arthritis), and TC-5214, our neuroscience collaboration with Targacept, also entered Phase III development
- Agreement with HealthCore, which maintains the largest commercially insured population data environment in the US, enables real world studies of health outcomes
- Portfolio of more than 100 generic products being licensed across 30 Emerging Markets for marketing under our brand
- Crestor substance patent upheld in the US courts
- Ranked in the top 8% in the sector in the Dow Jones Sustainability World and European Indexes
- Reviewed and revised Responsible Business Plan to align it with strategic business priorities
- Additional ways of reporting sales and marketing performance introduced to support increased transparency
- Improvement in senior leader communications with employees but slight decline in employee engagement
All growth rates are at CER
